Oncotargets and Therapy Dovepress

association between MDM2 snP309 T.g polymorphism and the risk of bladder cancer: new data in a chinese population and an updated meta-analysis Objective: Human murine double minute 2 protein (MDM2) is mainly a negative regulator of p53 tumor suppressor pathway. We aimed to investigate the association between MDM2 SNP309 polymorphism and bladder cancer risk. Methods: A total of 535 bladder cancer patients and 649 health controls were recruited for our study. MDM2 SNP309 T.G polymorphism was genotyped by polymerase chain reaction-ligase detection reaction method. Logistic regression was used to analyze the relationship between the genotype and susceptibility of bladder cancer. Kaplan–Meier estimates and log-rank test were obtained to analyze the association between the genotype and risk of recrudesce in nonmuscle-invasive bladder cancer patients. A multivariable Cox proportional hazards model was fitted to identify independent prognostic factors. To further investigate the association, we conducted a meta-analysis including six studies. Results: The frequency of the MDM2 SNP309 T.G polymorphism showed no significant difference between cases and controls (all P.0.05). In the stratification analysis, the results showed that G allele carriers were prone to have a significant decrease in risk of low-grade bladder cancer (adjusted odds ratio: 0.613, 95% confidence interval: 0.427–0.881), and G variant was associated with a significantly reduced risk of recurrence in nonmuscle-invasive bladder cancer patients with or without chemotherapy (P,0.05). The results of the meta-analysis showed that G allele and GG genotype of MDM2 SNP309 polymorphism were significantly associated with increased risk of bladder cancer in Caucasians (both P,0.05), and no association was observed in total populations and Asians (P.0.05). Conclusion: MDM2 SNP309 T.G polymorphism has no influence on bladder cancer risk in Asians, but this single nucleotide polymorphism may be associated with genetic susceptibility of bladder cancer among Caucasians.

[1]  D. Rubinsztein,et al.  Mammalian Autophagy: How Does It Work? , 2016, Annual review of biochemistry.

[2]  S. Pascolo.  Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. , 2016, European journal of pharmacology.

[3]  Gregory McAllister,et al.  Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy , 2015, Proceedings of the National Academy of Sciences.

[4]  Edward S. Kim,et al.  Lung cancer biomarkers, targeted therapies and clinical assays. , 2015, Translational lung cancer research.

[5]  J. Xiong.  Atg7 in development and disease: panacea or Pandora’s Box? , 2015, Protein & Cell.

[6]  F. Inagaki,et al.  Mechanisms of Autophagy. , 2015, Annual review of biophysics.

[7]  R. Herbst,et al.  Lung Cancer in the Era of Precision Medicine , 2015, Clinical Cancer Research.

[8]  Qi-chao Xie,et al.  MDM2 SNP309 variation confers the susceptibility to hepatocellular cancer: a meta-analysis based on 4271 subjects. , 2015, International journal of clinical and experimental medicine.

[9]  E. Sausville,et al.  Autophagy modulation: a target for cancer treatment development , 2015, Cancer Chemotherapy and Pharmacology.

[10]  Sheng Li,et al.  Genetic Variations rs11892031 and rs401681 Are Associated with Bladder Cancer Risk in a Chinese Population , 2014, International journal of molecular sciences.

[11]  M. Stern,et al.  Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai , 2014, International journal of cancer.

[12]  Chang S. Chan,et al.  Autophagy is required for glucose homeostasis and lung tumor maintenance. , 2014, Cancer discovery.

[13]  Zhi-hong Xu,et al.  Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells. , 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[14]  P. Sykacek,et al.  A dual role for autophagy in a murine model of lung cancer , 2014, Nature Communications.

[15]  N. Mizushima,et al.  Autophagy and human diseases , 2013, Cell Research.

[16]  E. White,et al.  Autophagy-Mediated Tumor Promotion , 2013, Cell.

[17]  Amy Y. M. Au,et al.  p53 status determines the role of autophagy in pancreatic tumour development , 2013, Nature.

[18]  A. Hartmann,et al.  Mdm2 SNP309 G-Variant Is Associated with Invasive Growth of Human Urinary Bladder Cancer , 2013, Pathobiology.

[19]  E. White,et al.  Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. , 2013, Cancer discovery.

[20]  Shan Li,et al.  An Updated Meta-Analysis on the Association of MDM2 SNP309 Polymorphism with Colorectal Cancer Risk , 2013, PloS one.

[21]  Chen Jiang,et al.  T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. , 2013, International journal of pharmaceutics.

[22]  T. Jacks,et al.  Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. , 2013, Genes & development.

[23]  R. Perez-soler,et al.  The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  L. Kiemeney,et al.  Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.

[25]  Long Yu,et al.  Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: A meta‐analysis , 2012, International journal of urology : official journal of the Japanese Urological Association.

[26]  D. Rubinsztein,et al.  Autophagy modulation as a potential therapeutic target for diverse diseases , 2012, Nature Reviews Drug Discovery.

[27]  Bo Zhu,et al.  MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects , 2012, Leukemia & lymphoma.

[28]  E. White.  Deconvoluting the context-dependent role for autophagy in cancer , 2012, Nature Reviews Cancer.

[29]  A. Thorburn,et al.  Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy , 2012, Autophagy.

[30]  H. Coller,et al.  Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. , 2011, Genes & development.

[31]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[32]  R. D. Mittal,et al.  Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. , 2010, DNA and cell biology.

[33]  K. Otsu,et al.  Discovery of Atg5/Atg7-independent alternative macroautophagy , 2009, Nature.

[34]  H. Nishiyama,et al.  Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. , 2008, Oncology reports.

[35]  Q. Wei,et al.  A Novel Functional Polymorphism C1797G in the MDM2 Promoter Is Associated with Risk of Bladder Cancer in a Chinese Population , 2008, Clinical Cancer Research.

[36]  N. Malats,et al.  Risk of Bladder Cancer Associated with Family History of Cancer: Do Low-Penetrance Polymorphisms Account for the Increase in Risk? , 2007, Cancer Epidemiology Biomarkers & Prevention.

[37]  R. Dahiya,et al.  MDM2 SNP309 Polymorphism as Risk Factor for Susceptibility and Poor Prognosis in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[38]  D. Rubinsztein,et al.  Potential therapeutic applications of autophagy , 2007, Nature Reviews Drug Discovery.

[39]  A. Levine,et al.  A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans , 2007, Oncogene.

[40]  T. Ozcelik,et al.  MDM2 T309G polymorphism is associated with bladder cancer. , 2006, Anticancer research.

[41]  A. Llombart‐Bosch,et al.  Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. , 2006, European urology.

[42]  D. Wei,et al.  A novel method based on ligase detection reaction for low abundant YIDD mutants detection in hepatitis B virus. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[43]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[44]  Guillermina Lozano,et al.  MDM2, an introduction. , 2003, Molecular cancer research : MCR.

[45]  D. Lane,et al.  Improving cancer therapy by non-genotoxic activation of p53. , 2003, European journal of cancer.

[46]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[47]  P. Hartge,et al.  Familial and environmental interactions in bladder cancer risk , 1985, International journal of cancer.

[48]  Hui Zhou,et al.  The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: a meta-analysis. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[49]  Xinbing Sui,et al.  Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer. , 2014, Molecular and clinical oncology.

[50]  Jun Liu,et al.  MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[51]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[52]  Peter Boyle,et al.  Tobacco smoking and cancer: A meta‐analysis , 2008, International journal of cancer.

[53]  P. F. Adams,et al.  Health behaviors of adults: United States, 2002-04. , 2006, Vital and health statistics. Series 10, Data from the National Health Survey.

[54]  C. Harris,et al.  TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. , 2004, IARC scientific publications.

[55]  A. Levine,et al.  Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. , 1999, Cancer research.